Lates News

According to each AI news, on August 21st, Cinda Securities released a research report granting a buy rating to Wanfu Biotechnology (300482.SZ). The main reasons for the rating include: 1) the recovery of the toxicology business growth, while infectious disease and chronic disease testing are under pressure; 2) short-term profitability pressure, with long-term growth driven by innovation. (Daily Economic News)